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Currently, a seven-day, triple-drug regimen has been recommended as one of the first-line therapies for 
Helicobacter pylori management in which clarithromycin is a key component. Development of 
clarithromycin resistance leads to the long term assessment of the efficacy of clarithromycin in the 
triple-drug regimen. The aim of this study was to rapidly and directly assess clarithromycin resistance 
point mutations on gastric biopsy specimens by using PCR-RFLP method. Biopsy samples were 
obtained over a 6-months period of 2009, from 200 dyspeptic patients referred to Shahrekord University 
of Medical Sciences, Iran. Initially, rapid urease test was performed and then DNA was isolated from 
each tissue and used for molecular analysis such as PCR (for H. pylori diagnostic) and PCR-RFLP (for 
Cla resistance determination). RUT and PCR results showed that 164 (82%) of the patients were H. 
pylori-positive. Resistance was evaluated in 164 samples by using enzymes BsaI and MboII. Thirty nine 
(39) (23/78%) clarithromycin-resistant strains were detected which were identified as 15 (9.15%) 
A2143G, 15 (9.15%) A2142G and 9 (5.49%) mix strains. The results showed that PCR-RFLP method had 
a high accuracy to detect A2142G and A2143G mutations associated with resistance to clarithromycin 
in the minimum possible time. 
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Helicobacter pylori infects about 50% of the world’s 
population and is thus a major source of gastritis, gastric 
ulcer, duodenal ulcer and an important risk factor for 
gastric cancer (Alarcon, 2000, 2003; Fontana, 2003; Lee 
et al., 2005; Kargar, 2010). It is widely known that all 
patients with gastric or duodenal ulcer and H. pylori 
infection should be treated with antimicrobial agents, 
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polymerase chain reaction-restriction fragment length 
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test. 
disease and efficiently prevents relapses (Lee, 2005; Liu, 
2008; Lottspeich, 2007; Occhialini, 1997). 
The most advocated therapy, triple therapy, often 
includes clarithromycin (Fontana, 2003; Occhialini, 1997). 
However, clarithromycin resistance in H. pylori has been 
shown to occur at different rates (1 to 10%) in different 
countries and is an important cause of the failure of these 
regimens (Occhialini et al., 1997). The mechanisms of 
clarithromycin resistance have been elucidated and 
consist of a mutation in the functional domains of the 23S 
rRNA in H. pylori, which is located in domain V. In 
particular, the main 23S rRNA mutations are an adenine-
to-guanine transition at positions 2142 and 2143. These 
single point mutations also generate specific restriction 
sites, namely BsaI and MboII, which can be used for the 
rapid screening of clarithromycin resistance (Alarcon, 
2003; Fontana, 2003; Lee, 2005). Successful detection of  




these mutations in cultured strains or gastric biopsy 
specimens has been described by the use of fluorescent 
in situ hybridization, PCR-restriction fragment length 
polymorphism, reverse hybridization line probe assay, 
PCR and EIA of DNA, and several real-time PCR 
methods (Lottspeich et al., 2007). The aim of this study 
was to rapidly and directly assess clarithromycin 
resistance point mutations on gastric biopsy specimens 
by using PCR-RFLP method. 
 
 
MATERIALS AND METHODS 
 
A total of 200 patients with a median age of 52.5 years (range, 17 
to 88 years) presenting with upper gastrointestinal symptoms during 
June 2009 to November 2009, were enrolled in the study. All 
patients read and signed an ‘informed consent’ form at the 
beginning of endoscopy and declared their satisfaction with the 
application of their anonymous data for research purpose.  
A rapid urease test (RUT) for the detection of urease activity of 
H. pylori was performed with a Gastro urease kit (Bahar-afshan, 
Iran) on biopsy samples. DNA was isolated from each tissue with a 
DNA extraction kit (DNP
TM
, CinnaGen, Iran) according to the 
manufacturer’s instruction and immediately used for molecular 
analysis such as PCR (for H. pylori diagnostic) and PCR-RFLP (for 
clarithromycin resistance determination). 
 
 
H. pylori detection in gastric biopsy samples by PCR 
 
H. pylori was detected with the PCR amplification method for a 
portion of the 16S rRNA gene. The reaction was performed directly 
on eluates obtained from gastric sample purification. One 
microliters of purified DNA was added to each PCR amplification 
reaction. The reaction was performed with a couple of primers 
whose nucleotide sequence was derived from a known sequence of 
the 16S rRNA gene: HP-1 forward (5′-CTGGAGAGACTAAG 
CCCTCC-3′) and Hp-2 reverse (5′-ATTACTGACGCT GATTGTGC-
3′) (Alarcon et al., 2000). Amplification reaction mixtures (24 µl) 
contained 1 µl of extracted DNA, 200 mM (each) deoxynucleoside 
triphosphates (dNTPs) (dNTP Mix, CinnaGen, Iran), 0.2 mM (each) 
primer (CinnaGen, Iran), 1.5 mM MgCl2 and 1 U of Taq polymerase 
(CinnaGen, Iran) in PCR buffer (CinnaGen, Iran). Amplification was 
carried out in an Eppendorf master cycler gradient (eppendorf, 
Germany). Thirty (30) cycles, each consisting of 1 min at 95°C, 1 
min at 58°C and 1 min at 72°C, were performed after 5 min of 
denaturing at 95°C. Cycles were followed by a final elongation at 
72°C for 5 min. The Hp16S fragment was visualized after 






A 1,400-bp fragment of the 23S rRNA gene was amplified with 
primers Cla-18 (5′-AGTCGGGACCTAAGGCGAG-3′) and Cla-21 
(5′-TTCCCGCTTAGATGCTTTCAG-3′). PCR amplification of DNA 
was performed in a final volume of 24 µl PCR mixture, containing 2 
µl of extracted DNA, 200 mM of each dNTPs, 0.2 mM of each 
primers, 1.5 mM MgCl2 and 1 U of Taq polymerase in PCR buffer. 
Amplification was carried out in an Eppendorf master cycler 
gradient over 30 cycles, each for 1 min at 95°C, 1 min at 62°C and 
1 min at 72°C. These cycles were performed after a denaturation of 
5 min at 95°C and a final elongation step at 72°C for 5 min. 
The amplicon was digested with BsaI (Fermentas GMBH, 





for 1 h at 37°C to detect the restriction site occurring when the 
mutation was A to G at 2143 or 2142, respectively. The restriction 





Detection of H. pylori directly in gastric biopsy 
samples 
 
RUT results showed that 164 (82%) of the patients were 
H. pylori-positive. DNA samples were derived from 
gastric biopsy samples of confirmed H. pylori-positive 
patients which were positive by the diagnostic PCR 
assays for the 16S rRNA and 23S rRNA targets. Both 
PCR assay confirmed the presence of H. pylori in all the 
164 biopsy samples (100%) and generated the expected 
PCR product of 109 and 1400 bp in 16S rRNA and 23S 





Thirty-nine (39) resistant strains were detected by PCR-
RFLP and were distributed as follows: 15 pure A2143G 
genotype, 15 pure A2142G genotype, 6 wild type/ 
A2143G genotypes, one wild type/A2142G genotype and 
two A2143G/A2142G genotypes. BsaI cuts the PCR 
product of the wild-type sequence into two fragments of 
1,000 and 400 bp and that of the A2143G sequence into 
three fragments of 700, 400 and 300 bp. MboII cuts the 
PCR product into two fragments of 700 bp only when 





All 164 cases found to be H. pylori positive by the RUT, 
were also PCR positive. It is important to emphasize that 
the PCR assay confirmed all results from phenotypic test 
(Lottspeich et al., 2007). 
Following the recognition of the important pathogenic 
role of H. pylori infection in the development of gastro-
duodenal diseases, there has been a continuous search 
for improved eradication therapy. Clarithromycin emerged 
as one of the antibiotics of choice because of its low MIC, 
which is relatively unaffected by lowering the pH, as well 
as its high concentration in gastric mucosa. In binding 
experiments, the tightest interaction for a macrolide-
ribosome complex observed to date was found for the 
binding of clarithromycin to H. pylori ribosomes. However, 
clarithromycin used as a single antibiotic cannot 
eradicate more than 70% of strains, and resistant strains 
have been isolated from patients who were not cured. 
When a second antibiotic was added, the success rate 
increased to about 90% but resistant strains were still 
isolated from case failures (Occhialini et al., 1997). 







Figure 1. 109 bp PCR product of 16S rRNA PCR for 
confirming H. pylori in gastric biopsy specimens. (M): 100 bp 
marker (100 to 1000 bp, Fermentas GMBH, Germany), (1): 
Positive control (obtained from Biotechnology Research Center 
of Islamic Azad University, Shahrekord Branch), (2 to 4): H. 




completely with A2142G and A2143G transition muta-
tions in the 23S rRNA gene, resulting in a decrease in the 
affinity of clarithromycin to bind to ribosomes. The high 
incidence of clarithromycin resistance in adults may 
reflect frequent prescriptions of macrolides for treatment 
of respiratory tract infections other than H. pylori. Some 
investigators have recently reported the predominance of 
an A2143G mutation in primary resistance isolates in 
Europe. This predominance was not shown in Korean 
and Brazilian study, and the A2142G mutation was 
predominant. Since the H. pylori genome is known to 
contain a high degree of genetic variability, Iranian H. 
pylori isolates may be similar to Western isolates of H. 
pylori and different from Korean and Brazilian isolate 
(Lee, 2005; Ribeiro, 2003). 
Treatment failure should prompt endoscopy, culture 
and susceptibility test. Retreatment should exclude anti-
biotics with acquired resistance. Many studies have 
highlighted the difficulties in retreatment, and it can be 
stated that the best available first-line treatment regimen 
is still the best rescue treatment. The H. pylori eradication 
rate was significantly improved when antibiotic therapy 
was performed on the basis of the results of antimicrobial 
susceptibility test (17 to 18% improvement in different 
report) (Lee et al., 2005). 
Resistance to clarithromycin is the main predictor of 
failure for eradication treatments using this compound, 
and the detection of resistance is mainly important. 
Detection of resistance in H. pylori is generally performed 
by MIC determination. This method requires growth of 
bacteria and takes at least 10 days; thus, the applicability  






Figure 2. RFLP result. (1): A2142G positive control; (2) 
A2142G negative control; (3) A2142G positive strain; (4): 
A2143G positive control; (5): A2143G negative control; (6): 
A2143G positive strain. Final lane is 100 bp marker (100 to 
3000 bp, Fermentas GMBH, Germany). All positive controls 
are obtained from Biotechnology Research Center of Islamic 
Azad University, Shahrekord Branch and negative controls 




of the data in the clinical setting is sometimes contro-
versial. PCR-RFLP method provides a result within few 
hours once the strain has been isolated, and no special 
technology apart from PCR is needed. The results could 
be more practical if the method were applied directly to 
biopsy specimens, which would provide a faster result 
(Alarcon et al., 2000). 
Unlike indirect assays such as ELISA and 
13
C-UBT, 
PCR assays are direct assays to detect H. pylori 
infection. Thus, these assays should result in higher 
specificity than the indirect assays. H. pylori colonizes on 
the apical surface of stomach's epithelial cells and sheds 
into gastric juice with the regular renewal of gastric 
mucosa. Several PCR assays based on H. pylori DNA 
from gastric juice/biopsy sample were reported for the 
detection of H. pylori infection. The possible H. pylori-
specific target genes included ureA, ureB, ureC, ureD, 
16S rRNA and 23S rRNA. Point mutations of 23S rRNA 
were closely related to formation of clarithromycin 
resistance (Liu et al. 2008). Since the PCR product of 
23S rRNA described in this study could be used as a 
biomarker to detect H. pylori infection and clarithromycin 
resistance simultaneously, this assay has advantages 
over other PCR-based methodologies. However, the 
specificity and sensitivity of the 23S rRNA PCR assay 
was not evaluated extensively. No single test is accepted 
as the standard for diagnosis of H. pylori infection. 
We have assessed a simple, rapid and cost-effective 
procedure which can detect H. pylori in gastric biopsy 
specimens with good sensitivity and evaluated the 
clarithromycin resistance of the microorganism. The 
second aspect of the development of this procedure  was  




the combination of knowledge, concerning all restriction 
sites associated with 23S rRNA mutations (those asso-
ciated with high resistance phenotypes) and therefore 
clarithromycin resistance. The result has been rapid 
endonuclease restriction analysis of the amplicons which 
is easy to perform and does not present any difficulty in 
interpretation. 
In conclusion, our PCR detection of H. pylori in gastric 
biopsy specimens is reliable and easy to perform and can 
provide additional information, specifically related to the 
macrolide susceptibility of the microorganism. Therefore, 
the extensive use of this method not only isolate H. pylori 
infecting the patient, but also direct the first eradication 
therapy or evaluation of the outcome of previous 
eradication regimens of the patient (with a consequent 
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